HC Wainwright downgrades BLCO as shorts exit after earnings surge

Bausch + Lomb jumped 14.5% last week after a 15.8% post-earnings pop on 28 October. HC Wainwright responded on 2 November by cutting the stock to Neutral from Buy, raising its target to $22 from $21 while the shares traded at $20. The firm's Yi Chen had reiterated Buy as recently as August.

Analysts split after the earnings move

The HC Wainwright downgrade was the one contrarian note in an otherwise constructive post-earnings round. JP Morgan raised its target to $22 from $16, maintaining Neutral. Citigroup lifted its target to $23 from $21 on a maintained Buy. RBC Capital moved to $23 from $21 on a maintained Outperform. Wells Fargo raised to $19 from $18, staying Equal-Weight. The consensus mean target sits at $21.64, a thin margin above the $20 close.

The bull case centres on MIEBO's differentiated position in dry eye, premium daily SiHy contact lenses, and a 2027 premium IOL launch. The bear case flags MIEBO revenue risk against FY2026 guidance, weaker OTC consumer demand, and a contact lens trajectory that may fall short.

EPS momentum factor scores support the bulls for now: 93rd percentile on 30-day EPS momentum and 91st percentile on 90-day, with a 94th-percentile analyst recommendation differential.

Shorts are leaving

Short interest fell 17.6% over the past week to 0.69% of free float, the lowest level in months. At that level the short position is small enough to be noise rather than a structural bear trade.

The lending market confirms the retreat. Availability now stands at 2,241% of estimated short interest, up 305% week on week. There are roughly 22 shares available to borrow for every one already lent out. Cost to borrow has fallen 55.6% over the week to 0.59%. The lending pool is as loose as it has been all year. The ORTEX short score has dropped from 61.9 on 19 October to 43.2 as of 29 October, a 19-point fall in 10 days.

Against the stock's closest peers, which posted a median gain of 27.9% over the same week, the 14.5% move looks restrained. Glaukos gained 32.8% and AXONICS rose 29.7%. BLCO's relative underperformance despite a strong print may partly reflect the post-earnings analyst recalibration.

Retail attention is elevated

Wikipedia views for Bausch + Lomb are running at a z-score of 2.81 against the prior 90 days as of 22 October, per ORTEX Alt Data from the Wikimedia Foundation. That is a measure of attention, not a revenue indicator, but it suggests the post-earnings move drew retail interest above what recent history would predict.

Bausch Health Companies still holds 86.9% of shares outstanding as the dominant registered holder. Icahn Capital holds 3.5 million shares as last disclosed. Davidson Kempner added 959,800 shares in the quarter to June. T. Rowe Price added 936,629 shares, last reported to September.

What to watch: The next earnings event is scheduled for 17 February 2027, 107 days away. The more immediate question is whether any of the five analysts who raised targets after October's print push further toward a rating upgrade if the stock consolidates above $20.

---

Data summary

• SI % of free float: 0.69%, down 17.6% week on week, lowest in months
• Short score: 43.2 (29 Oct), down from 61.9 on 19 Oct
• Availability: 2,241% of estimated SI, up 305% week on week
• Cost to borrow: 0.59%, down 55.6% over the week
• HC Wainwright: downgraded to Neutral, target raised to $22 from $21
• Consensus mean target: $21.64; stock closed at $20.00
• Stock: +14.5% past week; nearest peer median: +27.9%
• EPS momentum rank: 93rd percentile (30-day), 91st percentile (90-day)
• Next earnings: 17 February 2027